MCID: CNN010
MIFTS: 40

Connective Tissue Benign Neoplasm

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Benign Neoplasm

MalaCards integrated aliases for Connective Tissue Benign Neoplasm:

Name: Connective Tissue Benign Neoplasm 12 15
Soft Tissue Neoplasms 54 43 71
Soft Tissue Benign Neoplasm 12
Neoplasm of Soft Tissues 12
Tumor of the Soft Tissue 12
Neoplasm of Soft Tissue 12
Soft Tissue Neoplasm 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060123
MeSH 43 D012983
NCIt 49 C3377
SNOMED-CT 67 387837005
UMLS 71 C0037579

Summaries for Connective Tissue Benign Neoplasm

Disease Ontology : 12 A musculoskeletal system benign neoplasm that is located in connective tissue.

MalaCards based summary : Connective Tissue Benign Neoplasm, also known as soft tissue neoplasms, is related to sarcoma and chondroblastoma. An important gene associated with Connective Tissue Benign Neoplasm is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways is Bladder cancer. The drugs Cyclophosphamide and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include connective tissue, bone and liver, and related phenotypes are integument and neoplasm

Related Diseases for Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 sarcoma 32.9 SERPINA3 MDM2 KIT EWSR1 ENO2 CTNNB1
2 chondroblastoma 32.6 USP6 SERPINA3 H2AC18 ENO2
3 desmoid tumor 32.4 PAGR1 KIT HBEGF CTNNB1 CD34
4 glomangiosarcoma 32.4 PECAM1 MLANA CD34 CALD1
5 bone benign neoplasm 32.3 USP6 SERPINA3 ENO2 CDC73 CD1E
6 fibroma 32.1 USP6 SERPINA3 PECAM1 CTNNB1 CDC73 CD68
7 spindle cell sarcoma 31.3 SERPINA3 MDM2 CD34
8 myxoid liposarcoma 30.9 MDM2 EWSR1 CDK4
9 dermatofibrosarcoma protuberans 30.7 SERPINA3 MDM2 KIT ENO2 CDK4 CD34
10 infiltrating lipoma 30.7 MDM2 CDK4 CD34
11 alveolar soft part sarcoma 30.6 EWSR1 ENO2 CTNNB1
12 neurofibroma 30.6 MLANA KIT CD34
13 pleomorphic lipoma 30.6 SERPINA3 MDM2 CDK4 CD68 CD34
14 hemangiopericytoma, malignant 30.6 SERPINA3 PECAM1 MLANA MDM2 KIT ENO2
15 fasciitis 30.6 USP6 H2AC18 CD34
16 myositis ossificans 30.6 USP6 MDM2 CDK4
17 rhabdomyosarcoma 30.6 MDM2 KIT EWSR1 ENO2 CTNNB1 CDK4
18 epithelioid sarcoma 30.5 PECAM1 CD68 CD34
19 epithelioid leiomyosarcoma 30.5 SERPINA3 ENO2 CALD1
20 chondroid lipoma 30.5 CD68 CD34
21 plexiform schwannoma 30.5 KIT ENO2 CD34
22 perivascular epithelioid cell tumor 30.5 MLANA KIT CALD1
23 glomus tumor 30.5 ENO2 CD34 CALD1
24 hemangioma 30.5 PECAM1 KIT ENO2 CTNNB1 CD68 CD34
25 smooth muscle tumor 30.5 SERPINA3 KIT CD34 CALD1
26 chondrosarcoma, extraskeletal myxoid 30.5 EWSR1 ENO2 CD34
27 benign giant cell tumor 30.4 USP6 SERPINA3 H2AC18 CD68
28 soft tissue sarcoma 30.4 MDM2 EWSR1
29 merkel cell carcinoma 30.4 KIT ENO2 CTNNB1
30 granular cell tumor 30.4 SERPINA3 MLANA ENO2 CD68
31 rare tumor 30.3 KIT EWSR1
32 malignant peripheral nerve sheath tumor 30.3 MLANA MDM2 KIT CDK4 CD34
33 clear cell sarcoma 30.3 MLANA KIT EWSR1 ENO2
34 dedifferentiated liposarcoma 30.3 SERPINA3 MDM2 KIT EWSR1 CDK4 CD34
35 chondrosarcoma 30.3 SERPINA3 MDM2 EWSR1 ENO2 CDK4
36 neuroma 30.2 SERPINA3 KIT ENO2 CD68 CD34
37 malignant fibrous histiocytoma 30.2 SERPINA3 MDM2 KIT EWSR1 CDK4 CD68
38 leiomyosarcoma 30.2 SERPINA3 PECAM1 MLANA MDM2 KIT ENO2
39 sarcoma, synovial 30.2 SERPINA3 MDM2 KIT EWSR1 CTNNB1 CD34
40 liposarcoma 30.2 MDM2 EWSR1 CTNNB1 CDK4 CD68 CD34
41 neurilemmoma 30.2 SERPINA3 MLANA KIT ENO2 CD34
42 cutaneous fibrous histiocytoma 30.1 SERPINA3 PAGR1 MLANA FOXO4 CD68 CD34
43 pseudosarcomatous fibromatosis 30.1 USP6 SERPINA3 PECAM1 CTNNB1 CD68 CD34
44 myxofibrosarcoma 30.1 SERPINA3 PAGR1 MDM2 KIT EWSR1 CDK4
45 angiosarcoma 30.1 PECAM1 MLANA MDM2 KIT CD68 CD34
46 mesenchymal cell neoplasm 30.0 SERPINA3 PECAM1 MLANA KIT EWSR1 CD68
47 ewing sarcoma 30.0 MDM2 KIT EWSR1 ENO2 CDK4 CD34
48 well-differentiated liposarcoma 30.0 SERPINA3 MDM2 KIT EWSR1 CDK4 CD34
49 lipomatosis, multiple 30.0 SERPINA3 MLANA MDM2 KIT EWSR1 CDK4
50 fibrous histiocytoma 29.9 SERPINA3 PECAM1 KIT EWSR1 ENO2 CD68

Graphical network of the top 20 diseases related to Connective Tissue Benign Neoplasm:



Diseases related to Connective Tissue Benign Neoplasm

Symptoms & Phenotypes for Connective Tissue Benign Neoplasm

MGI Mouse Phenotypes related to Connective Tissue Benign Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.61 CD34 CDC73 CDK4 CTNNB1 HBEGF KIT
2 neoplasm MP:0002006 9.17 CD34 CDC73 CDK4 CTNNB1 FOXO4 KIT

Drugs & Therapeutics for Connective Tissue Benign Neoplasm

Drugs for Connective Tissue Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
4
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
5 Grape Approved Phase 3
6 Cranberry Approved, Investigational Phase 3
7
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
8
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
9
Ifosfamide Approved Phase 3 3778-73-2 3690
10
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
11
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
12
Daunorubicin Approved Phase 3 20830-81-3 30323
13
Camptothecin Experimental Phase 3 7689-03-4
14 Antirheumatic Agents Phase 3
15 Immunoglobulins Phase 3
16 Antibodies Phase 3
17 Antibodies, Monoclonal Phase 3
18 Etoposide phosphate Phase 3
19 Alkylating Agents Phase 3
20 Tubulin Modulators Phase 3
21 Immunosuppressive Agents Phase 3
22 Dermatologic Agents Phase 3
23 Immunologic Factors Phase 3
24 Podophyllotoxin Phase 3 518-28-5
25 Keratolytic Agents Phase 3
26 Antimitotic Agents Phase 3
27 Vaccines Phase 3
28 topoisomerase I inhibitors Phase 3
29 Antibiotics, Antitubercular Phase 3
30
Liposomal doxorubicin Phase 3 31703
31 Anti-Bacterial Agents Phase 3
32
Isophosphamide mustard Phase 3 0
33
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
34
Epinephrine Approved, Vet_approved Phase 1, Phase 2 51-43-4 5816
35
Racepinephrine Approved Phase 1, Phase 2 329-65-7 838
36
Silicon Approved, Investigational Phase 1, Phase 2 7440-21-3 4082203
37 Carboxymethylcellulose Sodium Phase 1, Phase 2
38 Epinephryl borate Phase 1, Phase 2
39
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
40
Lenograstim Approved, Investigational Phase 1 135968-09-1
41
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
42
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
43
Valproic acid Approved, Investigational Phase 1 99-66-1 3121
44
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
45
Cetuximab Approved Phase 1 205923-56-4 56842117 2333
46
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
47
Bevacizumab Approved, Investigational Phase 1 216974-75-3
48
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
49
Iodine Approved, Investigational Phase 1 7553-56-2 807
50 Anti-Inflammatory Agents Phase 1

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
2 Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
3 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Active, not recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
4 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
5 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
6 The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors Completed NCT00001189 Phase 2
7 SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES Completed NCT02066675 Phase 2 Trabectedin
8 Phase I Study of MEK162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors Recruiting NCT02285439 Phase 1, Phase 2 MEK162
9 Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on. Completed NCT03159585 Phase 1 TAEST16001
10 A Phase I Study to Determine the Dose of the Combination of Yondelis and Doxorubicin for Which Neutropenia is Manageable With the Support of Granulocyte-Colony Stimulation Factor in Subjects With Recurrent or Persistent Soft Tissue Sarcoma Completed NCT00102609 Phase 1 Doxorubicin;Trabectedin;Dexamethasone
11 Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics Recruiting NCT02441972 Phase 1 18F-Al-NOTA-PRGD2 PET/CT
12 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
13 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
14 A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies Not yet recruiting NCT04370587 Phase 1
15 A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Terminated NCT02602067 Phase 1
16 A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies Withdrawn NCT02915172 Phase 1 Lenvatinib;Capecitabine
17 Diagnostic Yield of Ultrasound-Guided Needle Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors Unknown status NCT03452644
18 Retrospective Clinical Outcome Study of Pediatric Dermatofibrosarcoma Protuberans: Single Institutional Experience of Twelve Cases From 1977-2002 Unknown status NCT00173355
19 Navigation Surgery for Bone and Soft Tissue Tumor Unknown status NCT01179698
20 Feasibility of the Third Space Robotic and Endoscopic Cooperative Surgery(TS-RECS) for Treating Gastric Stromal Tumor Completed NCT03804762
21 Radiofrequency Ablation of Painful Soft Tissue Neoplasms Completed NCT00041886
22 Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI Completed NCT01276483
23 Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors Completed NCT01630239 Early Phase 1
24 Quantitative MR Biomarkers for Sarcoma Treatment Completed NCT01017978
25 Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study Completed NCT02557243
26 In Vivo Identification of Peripheral Nerve Bundles During Surgery Using Optical Spectroscopy Techniques - a Pilot Study Completed NCT01731379
27 An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry Recruiting NCT02677961
28 Phase II Study to Evaluate Feasibility and Safety of Stereotactic Body Radiation Radiotherapy (SBRT) for Lung Metastases From Soft Tissue Sarcoma Recruiting NCT02561559
29 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Recruiting NCT03737734
30 Osteoarticular Tumor Characterization by Advanced Imaging Recruiting NCT02895633
31 Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors Recruiting NCT03751566 Standard supportive therapy
32 A Pilot Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin and Superficial Soft Tissue Tumors Recruiting NCT04377360
33 Follow-up of Recurrences of Limb Soft Tissue Sarcomas in Patients With Localized Disease: Performance of Ultrasound Recruiting NCT02834585
34 Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites. Active, not recruiting NCT00582647
35 Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II: Texture Analysis and Artificial Intelligence Not yet recruiting NCT04394052
36 Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt Not yet recruiting NCT04300179
37 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Malignant Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Not yet recruiting NCT03889899
38 A Safety and Preliminary Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia Not yet recruiting NCT03886181
39 The Use of Liposomal Bupivacaine (Exparel) in Soft Tissue Sarcoma Resection Suspended NCT03867188 Early Phase 1 Liposomal Bupivacaine
40 A Pilot Study of Photoacoustic Imaging (PAI) Suspended NCT03630601
41 A Feasibility Study to Evaluate the Safety and Effectiveness of ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound Treatment of Soft Tissue Tumors of the Extremities Terminated NCT01965002 Aspirin;Enoxaparin
42 Prospective Multi-center National Swiss Sarcoma Cohort Study Terminated NCT02775799

Search NIH Clinical Center for Connective Tissue Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


docetaxel

Cochrane evidence based reviews: soft tissue neoplasms

Genetic Tests for Connective Tissue Benign Neoplasm

Anatomical Context for Connective Tissue Benign Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Benign Neoplasm:

19
Connective Tissue

MalaCards organs/tissues related to Connective Tissue Benign Neoplasm:

40
Bone, Liver, Skin, Lung, Prostate, Endothelial, Nk Cells

Publications for Connective Tissue Benign Neoplasm

Articles related to Connective Tissue Benign Neoplasm:

(show top 50) (show all 486)
# Title Authors PMID Year
1
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. 61 54
16707369 2006
2
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. 61 54
16160477 2005
3
Desmoplastic stromal changes in cutaneous neural granular cell tumors: An under-recognized histopathologic feature of diagnostic and prognostic importance. 61
31859431 2020
4
Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma. 61
31913156 2020
5
Giant Granular Cell Tumor of the Cervical Spinal Cord Resected via Anterior Corpectomy with Reconstruction: Technical Note and Review of Literature. 61
32283320 2020
6
[Fine-needle biopsy of soft-tissue neoplasms: Case No.1]. 61
32340755 2020
7
Soft tissue tumor diagnosis: A three prong approach utilizing pattern analysis, immunocytochemistry, and molecular diagnostics. 61
31868988 2020
8
Bone Sarcomas and Desmoids. 61
31739943 2020
9
Genomic and transcriptomic features of dermatofibrosarcoma protuberans: Unusual chromosomal origin of the COL1A1-PDGFB fusion gene and synergistic effects of amplified regions in tumor development. 61
31870844 2020
10
Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma? 61
31889532 2020
11
Tumours in European Shorthair cats: a retrospective study of 680 cases. 61
32048893 2020
12
What is new in epithelioid soft tissue tumors? 61
31686193 2020
13
GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. 61
31189998 2019
14
Skin and superficial soft tissue neoplasms with multinucleated giant cells: Clinical, histologic, phenotypic, and molecular differentiating features. 61
31306855 2019
15
Is MRI diffusion-weighted imaging a reliable tool for the diagnosis and post-therapeutic follow-up of extremity soft tissue neoplasms? 61
31949339 2019
16
Asymptomatic esophageal glomus tumor: case report. 61
31602340 2019
17
PRRX-NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm. 61
31008539 2019
18
Isolated Breast Relapse after Metastatic Alveolar Rhabdomyosarcoma in a Young Premenarcheal Girl: What Could Have Been Done? 61
31911774 2019
19
Diffusion-weighted imaging and diffusion tensor imaging as adjuncts to conventional MRI for the diagnosis and management of peripheral nerve sheath tumors: current perspectives and future directions. 61
30535638 2019
20
Prevalence of Neoplasms among Former Adolescent Psychiatric Inpatients. 61
31389225 2019
21
[Myxoid soft tissue tumours : An algorithm for differential diagnosis]. 61
31168638 2019
22
Spindle Cell Sarcoma of the Paraspinal Musculature with Late Pulmonary Metastases. 61
31186400 2019
23
[Clinicopathological characteristics and differential diagnosis of interdigitating dendritic cell sarcoma]. 61
31216832 2019
24
MRI imaging of soft tissue tumours of the foot and ankle. 61
31161474 2019
25
Mesenchymal Tumors with EWSR1 Gene Rearrangements. 61
30709442 2019
26
Practical Application of Cytology and Core Biopsy in the Diagnosis of Mesenchymal Tumors. 61
30709446 2019
27
SWI/SNF Complex-Deficient Soft Tissue Neoplasms: A Pattern-Based Approach to Diagnosis and Differential Diagnosis. 61
30709441 2019
28
Large Undifferentiated Pleomorphic Sarcoma of the Posterior Thigh. 61
30853708 2019
29
Targeted RNA sequencing: A routine ancillary technique in the diagnosis of bone and soft tissue neoplasms. 61
30350361 2019
30
Multinucleate cell angiohistiocytoma of the lower vermilion lip: an unusual site. 61
27706113 2019
31
Granular Cell Tumor over the Mons Pubis: An Uncommon Tumor. 61
31223510 2019
32
Elevated eosinophil levels observed in infantile hemangioma patients from Kaifeng, China. 61
32047605 2019
33
Biphasic Epithelial Predominant Synovial Sarcoma Presenting as Painful Thigh Mass. 61
31583005 2019
34
Novel KHDRBS1-NTRK3 rearrangement in a congenital pediatric CD34-positive skin tumor: a case report. 61
30187166 2019
35
Limited biopsies of soft tissue tumors: the contemporary role of immunohistochemistry and molecular diagnostics. 61
30600320 2019
36
Imaging features of phosphaturic mesenchymal tumors. 61
29987349 2019
37
A novel case of an aggressive superficial spindle cell sarcoma in an adult resembling fibrosarcomatous dermatofibrosarcoma protuberans and harboring an EML4-NTRK3 fusion. 61
30175468 2018
38
Subcutaneous Phaeohyphomycosis: A Clinical Mimic of Skin and Soft Tissue Neoplasms-A Descriptive Study from India. 61
30105639 2018
39
Solitary fibrous tumor of the stomach with high-grade sarcomatous dedifferentiation. 61
30473761 2018
40
Paradoxical Examination and Imaging Findings in a Case of Paratesticular Cutaneous Angioyxoma. 61
29894778 2018
41
Pancreatic primitive neuroectodermal tumor: Focus on radiological features and differential diagnosis - A case report and literature review. 61
30249906 2018
42
Applications of Ancillary Testing in the Cytologic Diagnosis of Soft Tissue Neoplasms. 61
30190145 2018
43
Surgical management of truncal soft tissue sarcoma and other selected soft tissue neoplasms. 61
30173529 2018
44
Application of ancillary studies in soft tissue cytology using a pattern-based approach. 61
30156774 2018
45
Rapidly growing subcutaneous mass in an infant. 61
30142742 2018
46
Histology of ancient soft tissue tumors: A review. 61
29776878 2018
47
Cytologic diagnosis of round cell sarcomas in the era of ancillary testing: an updated review. 61
31043308 2018
48
Malignant granular cell tumors: the role of electron microscopy in the definitive diagnosis of an extremely aggressive soft tissue neoplasm. 61
29737916 2018
49
Large intramuscular lipoma of the tongue. 61
29904473 2018
50
An incidental finding of an asymptomatic intraneural glomus tumor: A case report and review of the literature. 61
29272030 2018

Variations for Connective Tissue Benign Neoplasm

Copy number variations for Connective Tissue Benign Neoplasm from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13803 1 1 56100000 Amplification Soft tissue tumor
2 21057 1 156500000 172900000 Amplification Soft tissue tumor
3 151970 20 27500000 41700000 Amplification Soft tissue tumor
4 178515 3 74200000 91000000 Amplification Soft tissue tumor
5 206336 6 139000000 161000000 Amplification Soft tissue tumor

Expression for Connective Tissue Benign Neoplasm

Search GEO for disease gene expression data for Connective Tissue Benign Neoplasm.

Pathways for Connective Tissue Benign Neoplasm

Pathways related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.66 MDM2 HBEGF CDK4

GO Terms for Connective Tissue Benign Neoplasm

Cellular components related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell periphery GO:0071944 8.8 PECAM1 CTNNB1 CD34

Biological processes related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hemopoiesis GO:0030097 9.5 KIT CTNNB1 CD34
2 stem cell population maintenance GO:0019827 9.43 KIT CTNNB1 CDC73
3 positive regulation of cell cycle G1/S phase transition GO:1902808 9.37 PAGR1 CDC73
4 endodermal cell fate commitment GO:0001711 9.16 CTNNB1 CDC73
5 response to water-immersion restraint stress GO:1990785 8.96 MDM2 FOXO4
6 glomerular endothelium development GO:0072011 8.62 PECAM1 CD34

Sources for Connective Tissue Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....